Physician profile
Andre S Chen
NPI 1902871221
$4,390.43
in general payments reported to CMS, 2019-2025
35 companies · $386 in 2025
The $386 reported for 2025 was more than what a typical Addiction Medicine (Family Medicine) provider received nationally (typical 2025 total: $143).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $843 · 2020: $243 · 2021: $346 · 2022: $374 · 2023: $1,033 · 2024: $1,166 · 2025: $386.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,585.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,585.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $1,959.74 | 2019-2025 | Octrode, Proclaim |
| Teva Pharmaceuticals USA, INC. | $252.37 | 2019-2022 | |
| Amgen INC. | $214.30 | 2019-2022 | |
| Horizon Therapeutics Plc | $204.90 | 2019-2020 | |
| Spr Therapeutics, INC | $182.55 | 2022-2023 | Sprint Pns System |
| Indivior INC. | $144.66 | 2019-2020 | |
| Abbvie INC. | $143.05 | 2019-2024 | Ubrelvy |
| Biodelivery Sciences International, INC. | $132.80 | 2019 | |
| Hikma Pharmaceuticals USA | $117.16 | 2022-2023 | Kloxxado |
| Scilex Pharmaceuticals INC. | $106.04 | 2019 | |
| Tonix Medicines, INC. | $84.05 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $80.17 | 2020-2023 | Relistor |
| Pfizer INC. | $72.11 | 2023-2024 | |
| Kaleo, INC. | $60.02 | 2019 | |
| Ucb, INC. | $56.47 | 2025 | Bimzelx |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $56.23 | 2019-2023 | Belbuca |
| Arbor Pharmaceuticals, INC. | $54.05 | 2019 | |
| Janssen Biotech, INC. | $52.43 | 2024-2025 | Tremfya |
| Biohaven Pharmaceuticals, INC. | $50.84 | 2021 | |
| Baudax Bio INC. | $50.07 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $39.65 | 2022 | |
| Radius Health, INC. | $35.32 | 2019 | |
| Mml US, INC. | $26.76 | 2023 | Reactiv8 |
| Ani Pharmaceuticals, INC. | $25.63 | 2025 | Purified Cortrophin Gel |
| Pylant Medical | $25.09 | 2025 | |
| Orexo US, INC. | $22.59 | 2019 | |
| Redhill Biopharma INC. | $21.90 | 2021 | |
| Alkermes, INC. | $21.10 | 2020 | |
| Medtronic, INC. | $21.02 | 2023 | Synchromedii |
| Grt US Holding, INC. | $16.82 | 2022 | |
| Novartis Pharmaceuticals Corporation | $13.31 | 2019 | |
| Emergent Biosolutions INC. | $12.55 | 2019 | |
| Boston Scientific Corporation | $11.97 | 2021 | |
| Ibsa Pharma INC. | $11.57 | 2021 | |
| Pernix Therapeutics Holdings, INC. | $11.14 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andre Chen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.